OneDigital Investment Advisors LLC Sells 8,375 Shares of DexCom, Inc. (NASDAQ:DXCM)

OneDigital Investment Advisors LLC reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 12.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,724 shares of the medical device company’s stock after selling 8,375 shares during the period. OneDigital Investment Advisors LLC’s holdings in DexCom were worth $3,937,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom in the 2nd quarter worth $25,000. Sachetta LLC lifted its holdings in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares in the last quarter. Crewe Advisors LLC bought a new position in shares of DexCom in the 1st quarter worth $29,000. Riverview Trust Co lifted its holdings in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC lifted its holdings in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Up 1.6 %

Shares of DexCom stock opened at $75.88 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The stock’s 50-day simple moving average is $69.89 and its 200 day simple moving average is $92.01. The stock has a market capitalization of $29.64 billion, a P/E ratio of 45.44, a P/E/G ratio of 2.22 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Analysts Set New Price Targets

DXCM has been the subject of a number of analyst reports. Piper Sandler reissued an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Raymond James lowered their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Sanford C. Bernstein increased their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Barclays lowered their price target on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Finally, Morgan Stanley lowered their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.